Heparin inhibits skeletal muscle growth in vitro.
Heparin or heparan sulfate proteoglycan (HeSPG), but not chondroitin sulfate or hyaluronic acid, exerts a pronounced inhibitory effect on muscle growth in vitro, as determined by total protein, myosin accumulation or synthesis, and [3H]thymidine incorporation studies. Primary muscle fibroblast culture growth is also inhibited by heparin but to a substantially lesser degree compared to muscle (30% and over 90% inhibition of growth, respectively). Heparin-induced inhibition of skeletal muscle growth is a consequence of its interaction with a growth factor(s) present in the media used to support myogenesis; heparin-Sepharose column absorbed horse serum can support muscle growth only in the presence of added heparin-binding growth factors like fibroblast growth factor (FGF) or chicken muscle growth factor (CMGF). Furthermore, heparin prevents the binding of iodinated FGF to the myoblast surface. We also show that the extent of muscle growth is a function of the relative amounts of heparin and FGF in culture. Finally, we provide evidence indicating that FGF can combine with endogenously occurring heparin-like components: immobilized FGF binds sodium-[35S]sulfate labeled components secreted in muscle culture conditioned medium, an interaction inhibited by anti-HeSPG antibodies or heparin, but not by other sulfated glycosaminoglycans. Since heparin binding growth factors not only stimulate myoblast proliferation but also actively inhibit the onset of muscle differentiation (G. Spitzz, D. Roman, and A. Strauss (1986). J. Biol. Chem. 261, 9483-9488), their interaction with naturally occurring heparin-like components may be an important physiological mechanism for modulating muscle growth and differentiation in development and regeneration.
Kardami
E
E
Department of Zoology, University of California, Berkeley 94720.
Spector
D
D
Strohman
R C
RC
D000818:Animals; D002478:Cells, Cultured; D002642:Chick Embryo; D005346:Fibroblast Growth Factors / Q000378:metabolism / Q000494:pharmacology; D005347:Fibroblasts; D006025:Glycosaminoglycans / Q000494:pharmacology; D006133:Growth Substances / Q000378:metabolism / Q000494:pharmacology; D006493:Heparin / Q000494:pharmacology*; D008934:Mitogens / Q000378:metabolism / Q000494:pharmacology; D024510:Muscle Development; D009124:Muscle Proteins / Q000096:biosynthesis; D009132:Muscles / Q000166:cytology / Q000187:drug effects*; D009218:Myosins / Q000096:biosynthesis
D006025:Glycosaminoglycans; D006133:Growth Substances; D008934:Mitogens; D009124:Muscle Proteins; D005346:Fibroblast Growth Factors; D006493:Heparin; D009218:Myosins